Patents Assigned to BIOPHYTIS
  • Patent number: 12551495
    Abstract: Disclosed are phytoecdysones and semisynthetic derivatives of phytoecdysones, intended to be used in treating impairment of the respiratory function in mammals, in particular in the context of a viral infection and more particularly during an infection by a coronavirus.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: February 17, 2026
    Assignees: BIOPHYTIS, SORBONNE UNIVERSITE
    Inventors: Pierre Dilda, René Lafont, Stanislas Veillet, Samuel Agus, Waly Dioh, Serge Camelo, Mathilde Latil, Mounia Chabane De Saint Aubin, Cendrine Tourette
  • Patent number: 12440500
    Abstract: Disclosed are 20-hydroxyecdysone and the derivatives thereof, intended for use in the treatment of a neuromuscular disease such as spinal muscular atrophy or amyotrophic lateral sclerosis, or more particularly in the treatment of a specific disorder of the motor neurons causing alterations in the muscular function occurring in the context of these neuromuscular diseases.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: October 14, 2025
    Assignees: BIOPHYTIS, SORBONNE UNIVERSITE
    Inventors: Mathilde Latil, Pierre Dilda, René Lafont, Stanislas Veillet
  • Patent number: 12215067
    Abstract: Disclosed is chemical compounds C that are derivatives of norbixin and have tropism for the eye, and are intended to be used in the treatment of eye diseases in mammals, in particular in the context of altering the retinal pigment epithelium and more particularly in the context of age-related macular degeneration (AMD) and Stargardt's disease.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: February 4, 2025
    Assignees: BIOPHYTIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), SORBONNE UNIVERSITE
    Inventors: Laurence Dinan, René Lafont, Pierre Dilda, Serge Camelo, Valérie Fontaine, Christine Balducci, Elodie Monteiro, Louis Guibout, Mathilde Latil, José-Alain Sahel, Stanislas Veillet
  • Patent number: 11542295
    Abstract: The invention relates to 20-hydroxyecdysone and the derivatives thereof, for use in the treatment of genetic myopathies.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: January 3, 2023
    Assignees: BIOPHYTIS, SORBONNE UNIVERSITÉ
    Inventors: Pierre Dilda, René Lafont, Mathilde Latil, Maria Serova, Onnik Agbulut, Stanislas Veillet
  • Publication number: 20200179407
    Abstract: The invention relates to 20-hydroxyecdysone and the derivatives thereof, for use in the treatment of genetic myopathies.
    Type: Application
    Filed: April 27, 2018
    Publication date: June 11, 2020
    Applicants: BIOPHYTIS, SORBONNE UNIVERSITE
    Inventors: Pierre DILDA, René LAFONT, Mathilde LATIL, Maria SEROVA, Onnik AGBULUT, Stanislas VEILLET
  • Publication number: 20200148718
    Abstract: The invention concerns a method for preparing an extract from a preparation of approximately 90% pure 20-hydroxyecdysone that comprises the following steps: g) Hot dissolution of approximately 90% pure 20-hydroxyecdysone in methanol, filtration and partial concentration, h) Addition of 1 to 5 volumes of acetone, i) Cooling to a temperature of between 0 and 5° C. while stirring, j) Filtration of the obtained precipitate, k) Successive rinses with acetone and water, and l) Drying.
    Type: Application
    Filed: April 30, 2018
    Publication date: May 14, 2020
    Applicants: BIOPHYTIS, SORBONNE UNIVERSITE
    Inventors: René LAFONT, Pierre DILDA, Waly DIOH, Philippe DUPONT, Susanna DEL SIGNORE, Stanislas VEILLET
  • Patent number: 10513503
    Abstract: Disclosed is a method for the treatment, prevention and/or stabilisation of ARMD, Stargardt disease, pigmentary retinopathy and/or diabetic retinopathy, including the application of a 3-deoxyanthocyanidin of formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and X? are as defined, with the condition that at least one of R1, R2, R3, R4 or R5 is a hydroxyl and at least one of R8, R9, R10 or R11 is a hydroxyl.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: December 24, 2019
    Assignees: BIOPHYTIS, SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
    Inventors: Valerie Fontaine, Rene Lafont, Jose-Alain Sahel, Stanislas Veillet
  • Patent number: 10316056
    Abstract: Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity. Also, a method of improving muscle quality in obese mammals and treating and/or preventing of obesity and associated complications and/or pathologies, advantageously type 2 diabetes and metabolic syndrome, using the chemical compounds.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: June 11, 2019
    Assignees: BIOPHYTIS, SORBONNE UNVERSITÉ
    Inventors: René Lafont, Waly Dioh, Sophie Raynal, Stanislas Veillet, Franck Lepifre, Jean-Denis Durand
  • Patent number: 10314804
    Abstract: A method of photoprotecting cells of the retinal pigment epithelium (EPR) in mammals using a composition having norbixin. The norbixin is produced by purification from an extract of Bixa orellana seeds.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: June 11, 2019
    Assignees: BIOPHYTIS, SORBONNE UNVERSITÉ
    Inventors: René Lafont, Stanislas Veillet, José-Alain Sahel, Valérie Fontaine, Pierre-Paul Elena
  • Patent number: 9938315
    Abstract: Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity. Also, a method of improving muscle quality in obese mammals and treating and/or preventing of obesity and associated complications and/or pathologies, advantageously type 2 diabetes and metabolic syndrome, using the chemical compounds.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: April 10, 2018
    Assignees: BIOPHYTIS, UNIVERSITÉ PARIS 6 PIERRE ET MARIE CURIE
    Inventors: René Lafont, Waly Dioh, Sophie Raynal, Stanislas Veillet, Franck Lepifre, Jean-Denis Durand